StockData
Beta Bionics, Inc. logo

Beta Bionics, Inc. (BBNX) stock

BBNXNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 11/304% below fair value
$14.33−0.39 (-2.65%)

Close on Nov 18, 2026Market cap $779.08MP/E –Yield –

Beta Bionics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Beta Bionics's revenue for the twelve months ending Sep 30, 2026 was $127.27M, up 43.7% year over year. For fiscal 2025 it was $100.25M, up 53.9% from the year before.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$100.25M+53.9%
FY2024Dec 31, 2024$65.12M+442.9%
FY2023Dec 31, 2023$12.00M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$35.51M+30.3%
Q2 FY2026Jun 30, 2026$32.01M+37.8%
Q1 FY2026Mar 31, 2026$27.63M+56.6%
Q4 FY2025Dec 31, 2025$32.12M+57.1%
Q3 FY2025Sep 30, 2025$27.25M+63.1%
Q2 FY2025Jun 30, 2025$23.24M+54.4%
Q1 FY2025Mar 31, 2025$17.64M+36.4%
Q4 FY2024Dec 31, 2024$20.44M–
Q3 FY2024Sep 30, 2024$16.71M–
Q2 FY2024Jun 30, 2024$15.05M–
Q1 FY2024Mar 31, 2024$12.93M–

More Beta Bionics figures

See a number that looks wrong?